Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Free Cash Flow (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Free Cash Flow for 7 consecutive years, with -$27.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 24.56% to -$27.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$149.6 million through Dec 2025, up 25.55% year-over-year, with the annual reading at -$149.6 million for FY2025, 25.55% up from the prior year.
  • Free Cash Flow hit -$27.9 million in Q4 2025 for Allogene Therapeutics, up from -$29.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$27.9 million in Q4 2025 to a low of -$70.1 million in Q1 2022.
  • Historically, Free Cash Flow has averaged -$50.9 million across 5 years, with a median of -$53.5 million in 2023.
  • Biggest five-year swings in Free Cash Flow: crashed 82.48% in 2021 and later soared 38.55% in 2025.
  • Year by year, Free Cash Flow stood at -$46.2 million in 2021, then fell by 28.38% to -$59.3 million in 2022, then increased by 9.09% to -$53.9 million in 2023, then soared by 31.42% to -$37.0 million in 2024, then grew by 24.56% to -$27.9 million in 2025.
  • Business Quant data shows Free Cash Flow for ALLO at -$27.9 million in Q4 2025, -$29.7 million in Q3 2025, and -$39.1 million in Q2 2025.